Lead sponsor
Shanghai JMT-Bio Inc.
2 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of November 5, 2026.
2
Trials led
2
Ongoing
134
Total enrollment
2
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
2
Trials by status
Recruiting
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese ParticipantsBMI ≥30Ph 1Recruiting90
Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy ParticipantsBMI 19-28Ph 1Recruiting44